Bayer Leveraging Consumer Growth From Product Launches, More Shelf Space
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Global consumer chief Erica Mann says OTC drug and nutritional product sales should increase during the current quarter as consumers' self-care focus turns to sunscreens and allergy treatments. Bayer plans around 30 consumer product launches later in the year.
You may also be interested in...
Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.